Attached files
file | filename |
---|---|
EXCEL - IDEA: XBRL DOCUMENT - Karyopharm Therapeutics Inc. | Financial_Report.xls |
EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc. | d824483dex311.htm |
EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc. | d824483dex321.htm |
EX-23.2 - EX 23.2 - Karyopharm Therapeutics Inc. | d824483dex232.htm |
EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc. | d824483dex312.htm |
EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc. | d824483dex211.htm |
EX-10.16 - EX-10.16 - Karyopharm Therapeutics Inc. | d824483dex1016.htm |
EX-10.21 - EX-10.21 - Karyopharm Therapeutics Inc. | d824483dex1021.htm |
EX-10.17 - EX-10.17 - Karyopharm Therapeutics Inc. | d824483dex1017.htm |
EX-10.22 - EX-10.22 - Karyopharm Therapeutics Inc. | d824483dex1022.htm |
10-K - 10-K - Karyopharm Therapeutics Inc. | d824483d10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-201366) of Karyopharm Therapeutics Inc. and |
(2) | Registration Statement (Form S-8 No. 333-194746) of Karyopharm Therapeutics Inc.; |
of our report dated March 13, 2015, with respect to the consolidated financial statements of Karyopharm Therapeutics Inc. included in this Annual Report (Form 10-K) of Karyopharm Therapeutics Inc. for the year ended December 31, 2014.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 13, 2015